Related Articles
Support my Velocity fundraiser and help Columbia solve cancer.
On October 6, I’ll be participating in Velocity. I’ve committed to raising crucial funds to help solve cancer at Columbia’s Herbert Irving Comprehensive Cancer Center…
Safety and Efficacy of SGLT2 Inhibitors for Amyloid Light-Chain Cardiomyopathy
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated benefit in patients with heart failure, but minimal data exists around the use of these medications in amyloid light-chain…
Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies
The Glasgow prognostic score (GPS) and CAR-HEMATOTOX (CAR-HT) score identify multiple myeloma (MM) patients at high risk for immune-mediated toxicity and early mortality with cellular…
Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies
The Glasgow prognostic score (GPS) and CAR-HEMATOTOX (CAR-HT) score identify multiple myeloma (MM) patients at high risk for immune-mediated toxicity and early mortality with cellular…
Safety and Efficacy of SGLT2 Inhibitors for Amyloid Light-Chain Cardiomyopathy
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated benefit in patients with heart failure, but minimal data exists around the use of these medications in amyloid light-chain…
Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis
This cohort study examines graded kidney response criteria and their association with kidney and overall survival for patients with kidney light chain amyloidosis.
Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy
Daratumumab’s incorporation in the upfront treatment of light chain (AL) amyloidosis has led to daratumumab (dara) refractoriness early in disease course. Patients who experience relapse…
TIMING AND OUTCOMES OF SECOND LINE THERAPY IN THE ERA OF… by Abdul-Hamid Bazarbachi
EHA Library; Bazarbachi A. Jun 13 2024; 421013;